Page 33 - Read Online

Page 8 of 9 Mudra et al. J Cancer Metastasis Treat 2019;5:27 I http://dx.doi.org/10.20517/2394-4722.2019.09

32. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol
Phys 2012;83:1306-10.
33. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, et al. Fractionated but not single-dose radiotherapy induces an
immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379-88.
34. Chicas-Sett R, Morales-Orue I, Rodriguez-Abreu D, Lara-Jimenez P. Combining radiotherapy and ipilimumab induces clinically relevant
radiation-induced abscopal effects in metastatic melanoma patients: a systematic review. Clin Transl Radiat Oncol 2017;9:5-11.
35. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the
possibility of longer survival. J Neurosurg 2012;117:227-33.
36. Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, et al. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer
2018;18:313-22.
37. Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, et al. Safety of combined pd-1 pathway inhibition and intracranial
radiation therapy in non-small cell lung cancer. J Thorac Oncol 2018;13:550-8.
38. Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for
brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys 2018;100:916-25.
39. Martin AM, Cagney DN, Catalano PJ, Alexander BM, Redig AJ, et al. Immunotherapy and symptomatic radiation necrosis in patients
with brain metastases treated with stereotactic radiation. JAMA Oncol 2018;4:1123-4.
40. Ahmed Kamran AK, Kim S, Arrington J, Naghavi AO, Dilling TJ. Outcomes targeting the PD-1/PD-L1 axis in conjunction with
stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol 2017;133:331-8.
41. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-3.
42. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N
Engl J Med 2010;363:1693-703.
43. Dugay F, Llamas-Gutierrez F, Gournay M, Medane S, Mazet F, et al. Clinicopathological characteristics of ROS1- and RET-rearranged
NSCLC in caucasian patients: data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK
alterations. Oncotarget 2017;8:53336-51.
44. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, et al. Brain metastases in patients with EGFR-mutated or ALK-
rearranged non-small-cell lung cancers. Lung Cancer 2015;88:108-11.
45. Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung
cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol 2018;13:1717-26.
46. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib in untreated EGFR-Mutated advanced non-
small-cell lung cancer. N Engl J Med 2018;378:113-25.
47. Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, et al. CNS response to osimertinib versus standard epidermal growth
factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-Mutated advanced non-small-cell lung cancer. J Clin Oncol
2018; doi: 10.1200/JCO.2018.78.3118.
48. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, et al. Inverse relationship between epidermal growth factor receptor expression
and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-90.
49. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, et al. Mechanisms of enhanced radiation response following
epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005;65:3328-35.
50. Soon YY, Leong CN, Koh WY, Tham IW. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small
cell lung cancer with brain metastases: a systematic review and meta-analysis. Radiother Oncol 2015;114:167-72.
51. Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, et al. Management of brain metastases in tyrosine kinase inhibitor-
naive epidermal growth factor receptor-mutant non-small-cell lung cancer: A retrospective multi-institutional analysis. J Clin Oncol
2017;35:1070-7.
52. Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, et al. A phase 3 trial of whole brain radiation therapy and stereotactic
radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases:
Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 2013;85:1312-8.
53. Wang W, Song Z, Zhang Y. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who
develop brain metastasis. Arch Med Sci 2018;14:1298-307.
54. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, et al. Clinical experience with crizotinib in patients with advanced alk-rearranged
non-small-cell lung cancer and brain metastases. J Clin Oncol 2015;33:1881-8.
55. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, et al. Alectinib versus crizotinib in untreated alk-positive non-small-cell lung cancer.
N Engl J Med 2017;377:829-38.
56. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung
cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017;390:29-39.
57. Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive
(ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol 2018;29:2214-22.
58. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma
kinase-positive non-small-cell lung cancer: a randomized, multicenter phase ii trial. J Clin Oncol 2017;35:2490-8.
59. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients
previously treated with crizotinib and ceritinib. J Thorac Oncol 2015;10:232-6.
60. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results
from a global phase 2 study. Lancet Oncol 2018;19:1654-67.
61. Griesinger F, Roeper J, Pottgen C, Willborn KC, Eberhardt WEE. Brain metastases in ALK-positive NSCLC - time to adjust current
treatment algorithms. Oncotarget 2018;9:35181-94.